The recombinant protein is produced via E. coli expression systems, optimized for high yield and stability . Post-purification steps involve Tris-based buffers with 50% glycerol to maintain solubility and functionality during storage at -20°C or -80°C .
MCT2 overexpression is linked to tumor progression in prostate and breast cancers, driven by epigenetic deregulation (e.g., promoter demethylation) .
Recombinant MCT2 enables in vitro studies on lactate shuttling in cancer microenvironments, particularly in models exploring metabolic crosstalk between adipocytes and carcinoma cells .
MCT2 supports oligodendrocyte function by importing lactate and ketone bodies for myelin maintenance. Knockdown studies in mice highlight its role in preventing axonal degeneration .
The gerbil variant may aid comparative studies of species-specific transporter efficiency .
Anti-MCT2 antibodies (e.g., Boster Bio A05214) utilize recombinant proteins as immunogens for Western blot validation in human and rat models .
Targeted Therapies: MCT2 inhibition is being explored to disrupt cancer metabolic pathways .
Neurodegenerative Diseases: Recombinant MCT2 could model therapeutic strategies for multiple sclerosis, given its role in oligodendrocyte metabolism .
Structural Biology: Cryo-EM studies using recombinant MCT2 may resolve substrate-binding dynamics and guide drug design.